Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 7/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27075244 | 0.95 | PDE2A (0.54) | PDE2APTGER4PTGER2HDAC3HDAC1 | |
| SCHEMBL28540955 | 0.82 | BCL2L1 (0.44) | HDAC3HDAC1HDAC2HDAC6APP | |
| SCHEMBL2362049 | 0.82 | TACR3 (0.44) | PDE2AHDAC1 | |
| SCHEMBL19282962 | 0.80 | PDE2A (0.46) | PDE2APTGER4PTGER2HDAC3HDAC1 | |
| SCHEMBL28113612 | 0.80 | PDE2A (0.58) | PDE2APTGER4PTGER2HDAC3HDAC1 | |
| SCHEMBL27159970 | 0.76 | PDE2A (0.44) | PDE2APTGER4PTGER2HDAC3HDAC1 | |
| SCHEMBL2363242 | 0.74 | HTT (0.48) | HDAC3HDAC1HDAC2HDAC6OPRM1 | |
| SCHEMBL27088175 | 0.74 | PDE2A (0.40) | PDE2APTGER4 | |
| SCHEMBL15258671 | 0.73 | HDAC3 (0.47) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL2720873 | 0.73 | MAPK1 (0.38) | PDE2AHDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170247336-A1 | SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247336-A1 | SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | PDE2A 962/4885PTGER4 2214/4885PTGER2 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.